THE OFFER: Actavis Inc. said Monday that it has agreed to buy fellow drugmaker Warner Chilcott PLC in an all-stock deal valued at about $8.5 billion.
THE PARTICULARS: Warner Chilcott shareholders will receive 0.16 shares of the new company for each share they own. This equals $20.08 per share, and they would then own a 23 percent stake in the new company.
Actavis shareholders will receive one share of the new company for each share they own.
HEADQUARTERS: The combined company will be based in Ireland, which offers a lower tax rate that analyst say is a key to the deal's success.